AGMB · Agomab Therapeutics NV
Market Cap
$655.49M
Shares
49.25M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.06
Open$14.00
Day$12.96–14.10
Available close range$9.61–17.82
Avg vol 30d148K
Short int878K · 1.8% float · 6.8d
Short vol54%
DataFeb 2026–Sep 2026
The closing range uses available history since Feb 6, 2026; less than a full year is stored.
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.8%
Latest settlement · 6.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−2%
below
RSI (14)
45
neutral
MACD trend
Negative
52-week position
42%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−6%
trailing
6-month return
+7%
trailing
Relative strength
−11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+6% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.78% of float · ▼ -6.7% MoM · 6.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
34 holders — 13F breadth
Squeeze score
54
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
93%
annualized · 1-yr
Max drawdown
−41%
past year
ATR
9.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−2%
Neutral
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
42%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+6% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.78% of float · ▼ -6.7% MoM · 6.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
34 holders — 13F breadth
Price context
position in its available closing range
Range low $10
Now $13 · 42%
Range high $18
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AGMB
this stock
Agomab Therapeutics NV
|
$655.49M | — | — | — | 1.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.60B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AGMB | -11.9% | -6.4% | +7.1% | -0.8% | — |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -10.8% | -4.6% | -10.7% | -0.5% | — |
Key facts
CIK
2020932
CUSIP
00860C102
13F (30d)
24 filings
24 filers
Visit website
Investor relations